The relevance of iron in the pathogenesis of Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 193-208

  Götz, Mario E ^a,d   Double, Kay ^b   Gerlach, Manfred ^a   Youdim, Moussa B H ^c   Riederer, Peter ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d UNIVERSITY OF KIEL   (Germany)

^e NONE   (Germany)

Author keywords

Dopamine; Iron; Lewy body; Neuromelanin; Oxidative stress; Parkinson's disease; Radicals; Substantia nigra; Transition metal; synuclein

Indexed keywords

ALPHA SYNUCLEIN; FERRITIN; IRON; NEUROMELANIN; REACTIVE OXYGEN METABOLITE;

BLOOD BRAIN BARRIER; BRAIN TISSUE; CADAVER; CYTOTOXICITY; DISEASE ACTIVITY; DISEASE SEVERITY; GLIA; HUMAN; LEWY BODY; NERVE CELL NECROSIS; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN LOCALIZATION; REVIEW; SUBSTANTIA NIGRA;

EID: 11144353557     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.017     Document Type: Review

References (129)

1. LAI, B.C.L., S.A. MARION, K. TESCHKE et al. 2002. Occupational and environmental risk factors for Parkinson's disease. Parkinson's Rel. Dis. 8: 297-309.
2. POWERS, K.M., T. SMITH-WELLER, G.M. FRANKLIN et al. 2003. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60: 1761-1766.
3. GORELL, J.M., C.C. JOHNSON, B.A. RYBICKI et al. 1997. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48: 650-658.
4. GORELL, J.M., C.C. JOHNSON, B.A. RYBICKI et al. 1999. Occupational exposure to manganese, copper, lead, iron, mercury, and zinc and the risk of Parkinson's disease. Neurotoxicology 20: 239-247.
5. RYBICKI, B.A., C.C. JOHNSON, E.L. PETERSON et al. 1999. A family history of Parkinson's disease and its effect on other PD risk factors. Neuroepidemiology 18: 270-278.
6. ZAYED, J., S. DUCIC, G. CAMPANELLA et al. 1990. Facteurs environnementaux dans l'etiologie de la maladie de Parkinson. Can. J. Neurol. Sci. 17: 286-291.
7. NGIM, C.H. & G. DEVATHASAN, 1989. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 8: 128-141.
8. SEIDLER, A., W. HELLENBRAND, B.P. ROBRA et al. 1996. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case control study in Germany. Neurology 46: 1275-1284.
9. LOGROSCINO, G., K. MARDER, J. GRAZIANO et al. 1998. Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13(suppl. 1): 13-16.
10. YOUDIM, M.B. & A.R. GREEN. 1976. Biogenic monoamine metabolism and functional activity in iron-deficient rats: behavioural correlates. Ciba Found. Symp. 7-9: 201-225.
11. YOUDIM, M.B.H. 1985. Brain iron metabolism: biochemical and behavioural aspects of iron in relation to dopaminergic neurotransmission. In Handbook of Neurochemistry. Volume 10, pp. 731-756. Plenum. New York.
12. YOUDIM, M.B., D. BEN-SHACHAR & P. RIEDERER. 1989. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126: 47-54.
13. YOUDIM, M.B., D. BEN-SHACHAR & P. RIEDERER. 1993. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8: 1-12.
14. HIRSCH, E.C. 1994. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol. Neurobiol. 9: 135-142.
15. JELLINGER, K.A. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140.
16. JELLINGER, K.A. 2003. General aspects of neurodegeneration. J. Neural Transm. Suppl. 65: 101-144.
17. BERG, D., M. GERLACH, M.B.H. YOUDIM et al. 2001. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79: 225-236.
18. BERG, D., W. ROGGENDORF, U. SCHRÖDER et al. 2002. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigro-striatal injury. Arch. Neurol. 59: 999-1005.
19. DOUBLE, K.L., M. GERLACH, M.B.H. YOUDIM & P. RIEDERER. 2000. Impaired iron homeostasis in Parkinson's disease. J. Neural Transm. Suppl. 60: 37-58.
20. DOUBLE, K.L., D. BEN-SHACHAR, M.B.H. YOUDIM et al. 2002. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 24: 621-628.
21. GERLACH, M., D. BEN-SIIACHAR, P. RIEDERER et al. 1994. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J. Neurochem. 63: 793-807.
22. GERLACH, M., K.L. DOUBLE, D. BEN-SHACHAR et al. 2003. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotoxicol. Res. 5: 35-44.
23. PERRY, G., L.M. SAYRE et al. 2002. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16: 339-352.
24. SIPE, J.C., P. LEE & E. BEUTLER. 2002. Brain iron metabolism and neurodegenerative disorders. Dev. Neurosci. 24: 188-196.
25. WOLOZIN, B. & N. GOLTS. 2002. Iron and Parkinson's disease. Neuroscientist 8: 22-32.
26. FRIEDMAN, A. & J. GALAZKA-FRIEDMAN. 2001. The current state of free radicals in Parkinson's disease: nigral iron as a trigger of oxidative stress. In Parkinson's Disease. Volume 86, pp. 137-142. Lippincott/Williams & Wilkins. Philadelphia.
27. HALLGREN, B. & P. SOURANDER. 1958. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3: 41-51.
28. RIEDERER, P., E. SOFIC, W-D. RAUSCH et al. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520.
29. GRIFFITHS, P.D., B.R. DOBSDN, G.R. JONES et al. 1999. Iron in the basal ganglia in Parkinson's disease: an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122: 667-673.
30. LHERMITTE, J., W.M. KRAUS & D. MCALPINE. 1924. On the occurrence of abnormal deposits of iron in the brain in parkinsonism with special reference to its localisation. J. Neurol. Psychopathol. 5: 195-208.
31. EARLE, K.M. 1968. Studies in Parkinson's disease including X-ray fluorescent spectroscopy of formalin-fixed tissues. J. Neuropathol. Exp. Neurol. 27: 1-14.
32. RIEDERER, P., E. SOFIC, W.D. RAUSCH et al. 1985. Dopaminforschung heute und morgen-L-Dopa in der Zunkunft. In L-Dopa Substitution der Parkinson-Krankheit, Geschichte-Gegenwart-Zukunft, pp. 127-144. Springer-Verlag. Wien.
33. DEXTER, D.T., F.R. WELLS et al. 1987. Increased nigral iron content in post-mortem parkinsonian brain. Lancet 341: 1219-1220.
34. SOFIC, E., P. RIEDERER, H. HEINSEN et al. 1988. Increased iron(II) and total iron content in post-mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74: 199-205.
35. DEXTER, D.T., J. SIAN, S. ROSE et al. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35: 38-44.
36. OWEN, A.D., A.H.V. SCHAPIRA, P. JENNER et al. 1997. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease, and dementia with Lewy bodies. J. Neural Transm. Suppl. 51: 167-173.
37. SOFIC, E., W. PAULUS, K. JELLINGER et al. 1991. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56: 978-982.
38. GOMORI, G. 1936. Microtechnical demonstration of iron. Am. J. Pathol. 12: 655-663.
39. DEXTER, D.T., F.R. WELLS, A.J. LEES et al. 1989. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52: 1830-136.
40. DEXTER, D.T., A. CARAYON, F. JAVOY-AGID et al. 1991. Alterations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953-1975.
41. JELLINGER, K., W. PAULUS, I. GRUNDKE-IQBAL et al. 1990. Brain iron and ferritin in Parkinson's and Alzheimer's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 2: 327-340.
42. JELLINGER, K., E. KIENZL, G. RUMPELMAIR et al. 1992. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59: 1168-1171.
43. JELLINGER, K., E. KIENZL, G. RUMPELMAIR et al. 1993. Iron and ferritin in substantia nigra in Parkinson's disease. In Parkinson's Disease. Volume 60, pp. 267-272. Raven Press. New York.
44. HIRSCH, E.C., J-P. BRANDEL, P. GALLE et al. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451.
45. UITTI, R.J., A.H. RAJPUT, B. ROZDILSKY et al. 1989. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can. J. Neurol. Sci. 16: 310-314.
46. MANN, V.M., J.M. COOPER, S.E. DANIEL et al. 1994. Complex 1, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36: 876-881.
47. LOEFFLER, D.A., J.R. CONNOR et al. 1995. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65: 710-716.
48. GALAZKA-FRIEDMAN, J., E.R. BAUMINGER, A. FRIEDMAN et al. 1996. Iron in parkinsonian and control substantia nigra: a Mössbauer spectroscopy study. Mov. Disord. 11: 8-16.
49. GERLACH, M., K. DOUBLE, P. RIEDERER et al. 1997. Iron in the parkinsonian substantia nigra. Mov. Disord. 12: 258-260.
50. GERLACH, M., A.X. TRAUTWEIN, L. ZECCA et al. 1995. Mössbauer spectroscopic studies of human neuromelanin isolated from the substantia nigra. J. Neurochem. 65: 923-926.
51. GOOD, P., C.W. OLANOW & D.P. PERL. 1992. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593: 343-346.
52. IANCU, T.C., D.P. PERL, I. STERNLIEB et al. 1996. The application of laser microprobe mass analysis to the study of biological material. Biometals 9: 57-65.
53. GORELL, J.M., R.J. ORDIDGE, G.G. BROWN et al. 1995. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143.
54. RYVLIN, P., E. BROUSSOLLE, H. PIOLLET et al. 1995. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch. Neurol. 52: 583-588.
55. YE, F.Q., P.S. ALLEN & W.R.W. MARTIN. 1996. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov. Disord. 11: 243-249.
56. BARTZOKIS, G., J.L. CUMMINGS, C.H. MARKHAM et al. 1999. MRI evaluation of brain iron in earlier-and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17: 213-222.
57. MARTIN, W.R.W. 2001. Magnetic resonance imaging and spectroscopy in Parkinson's disease. In Parkinson's Disease. Volume 86, pp. 197-203. Lippincott/Williams & Wilkins. Philadelphia.
58. BECKER, G., J. SEUFERT, U. BOGDAHN et al. 1995. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45: 182-184.
59. BERG, D., G. BECKER, B. ZEILER et al. 1999. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53: 1026-1031.
60. BERG, D., C. SIEFKER, P. RUPRECHT-DÖRFLER et al. 2001. Echo pattern of substantia nigra and its relevance for motor function and motility in elderly subjects. Neurology 56: 13-17.
61. WALTER, U., M. WITTSTOCK, R. BENECKE et al. 2002. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders, but increased in Parkinson's disease. J. Neural Transm. 109: 191-196.
62. ZECCA, L., D. BERQ, T. ARZBERGER et al. 2004. The in vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Neurology. Submitted.
63. CONNOR J., S. MENZIES, S. ST. MARTIN et al. 1990. The cellular distribution of transferrin, ferritin, and iron in the human brain. J. Neurosci. Res. 27: 595-611.
64. ZECCA, L., M. GALLORINI, V. SCHÜNEMANN et al. 2001. Iron, neuromelanin, and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76: 1766-1773.
65. RIEDERER, P., W.D. RAUSCH, B. SCHMIDT et al. 1988. Biochemical fundamentals in Parkinson's disease. Mt. Sinai J. Med. 55: 21-28.
66. MONTEIRO, H., G. VILLE & C. WINTERBOURN. 1989. Release of iron from ferritin by semiquinone, anthracycline, bipyridyl, and nitroaromatic radicals. Free Radical Biol. Med. 6: 587-591.
67. LAPENNA, D., S. DEGIOIA, G. CIOFANI et al. 1995. Captopril induces iron release from ferritin and oxidative stress. J. Pharm. Pharmacol. 47: 1-6.
68. LINERT, W., E. HERLINGER, R.F. JAMESON et al. 1996. Dopamine, 6-hydroxydopamine, iron, and dioxygen: their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316: 160-168.
69. DOUBLE, K.L., M. MAYWALD, M. SCHMITTEL et al. 1997. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70: 2492-2499.
70. MONTEIRO, H. & C. WINTERBOURN. 1988. The superoxide-dependent transfer of iron from ferritin to transferrin and lactoferrin. Biochem. J. 256: 923-928.
71. BOYER, R., T. GRABILL & R. PETROVICH. 1988. Reactive release of ferritin iron: a kinetic assay. Anal. Biochem. 174: 17-22.
72. HALLIWELL, B. & J. GUTTERIDGE. 1986. Iron and free radical reactions: two aspects of antioxidant protection. Trends Biol. Sci. 11: 1372-1375-
73. GÖTZ, M.E., G. KÜNIG, P. RIEDERER et al. 1994. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 63: 37-122.
74. DOUBLE, K.L., P. RIEDERER & M. GERLACH. 1998. The role of iron in 6-hydroxydopamine neurotoxicity. Adv. Neurol. 80: 287-296.
75. BEN-SHACHAR, D., P. RIEDERER & M.B.H. YOUDIM. 1991. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57: 1609-1614.
76. DOUBLE, K.L., M. GERLACH, V. SCHÜNEMANN et al. 2003. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66: 489-494.
77. ZECCA, L., D. TAMPELLINI, M. GERLACH et al. 2001. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 54: 414-418.
78. DOUBLE, K.L., L. ZECCA et al. 2000. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75: 2583-2589.
79. ZECCA, L. & H.M. SWARTZ. 1993. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural Transm. Parkinson's Dis. Dementia Sect 5: 203-213.
80. ZECCA, L., T. SHIMA, A. STROPPOLO et al. 1996. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73: 407-415.
81. SHIMA, T., T. SARNA, A. STROPPOLO et al. 1997. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radical Biol. Med. 23: 110-119.
82. HIRSCH, E.C., A.M. GRAYBIEL & Y.A. AGID. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345-348.
83. ZECCA, L., R. FARIELLO, P. RIEDERER et al. 2002. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510: 216-220.
84. KASTNER, A., E. HIRSCH, O. LEJEUNE et al. 1992. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59: 1080-1089.
85. GIBB, W. 1992. Melanin, tyrosine hydroxylase, calbindin, and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuron susceptibility in Parkinson's disease. Brain Res. 581: 283-291.
86. DOUBLE, K.L., P. RIEDERER & M. GERLACH. 1999. The significance of neuromelanin in Parkinson's disease. Drug News Dev. 12: 333-340.
87. PILAS, B., T. SARNA, B. KALYANARAMAN et al. 1988. The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radical Biol. Med. 4: 285-293.
88. CASTELLANI, R., S. SIEDLAK, G. PERRY et al. 2000. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100: 111-114.
89. 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease. Mov. Disord. 15: 977-981.
90. LOPIANO, L., M. CHIESA, D. DIGILIO et al. 2000. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta 1500: 306-312.
91. FAUCHEUX, B.A., M.E. MARTIN, C. BEAUMONT et al. 2003. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86: 1142-1148.
92. POLYMEROPOULOS, M., C. LAVEDAN, E. LEROY et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
93. KRÜGER, R., W. KUHN, T. MÜLLER et al. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18: 106-108.
94. MIZUNO, Y., N. HATTORI, T. KITADA et al. 2001. Familial Parkinson's disease, α-synuclein, and parkin. In Parkinson's Disease. Volume 86, pp. 13-21. Lippincott/ Williams & Wilkins. Philadelphia.
95. SPILLANTINI, M.G., M.L. SCHMIDT, V.M. LEE et al. 1997. α-Synuclein in Lewy bodies. Nature 388: 839-840.
96. SPILLANTINI, M.G., R.A. CROWTHER, R. JAKES et al. 1998. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95: 6469-6473.
97. MARKOPOULOU, K., Z. WSZOLEK, R. PFEIFFER et al. 1999. Reduced expression of the G209A α-synuclein allele in familial parkinsonism. Ann. Neurol. 46: 374-381.
98. OSTREROVA-GOLTS, N., L. PETRUCELLI et al. 2000. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20: 6048-6054.
99. TURNBULL, S., B.J. TABNER, O.M.A. EL-AGNAF et al. 2001. α-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radical Biol. Med. 30: 1163-1170.
100. 2+ binding to α-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276: 22680-22684.
101. HASHIMOTO, M., L.J. HSU, Y. XIA et al. 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 10: 717-721.
102. HASHIMOTO, M., E. ROCKENSTEIN & E. MASLIAH. 2003. Transgenic models of α-synuclein pathology. Ann. N.Y. Acad. Sci. 991: 171-188.
103. PAIK, S.R., H. SHIN, J. LEE et al. 1999. Copper(II)-induced self oligomerization of α-synuclein. Biochem. J. 340: 821-828.
104. PAIK, S.R., D.Y. LEE, H.J. CHO et al. 2003. Oxidized glutathione stimulated the amyloid formation of α-synuclein. FEBS Lett. 537: 63-67.
105. TABNER, B.J., S. TURNBULL, O.M.A. EL-AGNAF et al. 2002. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radical Biol. Med. 32: 1076-1083.
106. MÜNCH, G., H.J. LÜTH, A. WONG et al. 2000. Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat. 20: 253-257.
107. MÜNCH, G., J, GASIC-MILENKOVIC & T. ARENDT. 2003. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. J. Neural Transm. Suppl. 65: 63-71.
108. CONWAY, K.A., J.C. ROCHET, R.M. BIEGANSKI et al. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine alpha-synuclein adduct. Science 294: 1346-1349.
109. TABRIZI, S.J., M. ORTH, J.M. WILKINSON et al. 2001. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9: 2683-2689.
110. HSU, L.J., Y. SAGARRA, A. ARROYO et al. 2001. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157: 401-410.
111. SAHA, A.R., N.N. NINKINA, D.P. HANGER et al. 2001. Induction of neuronal death by α-synuclein. Eur. J. Neurosci. 12: 3073-3077.
112. KIM, K.S., S.Y. CHOI, H.Y. KWON et al. 2002. Aggregation of α-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Free Radical Biol. Med. 32: 544-550.
113. YOUDIM, M.B.H., G. STEPHENSEN & D. BEN SHACHAR. 2004. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. This volume.
114. FORLONI, G., I. BERTANI, A.M. CALELLA et al. 2001. α-Synuclein and Parkinson's disease: selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 47: 632-640.
115. LO BIANCO, C., J.L. RIDET, B.L. SCHNEIDER et al. 2002. α-Synucleinopathy and selective dopaminergic loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99: 10813-10818.
116. VOLLES, M.J., S.J. LEE, J-C. ROCHET et al. 2001. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819.
117. VOLLES, M.J. & P.T. LANSBURY, JR. 2002. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41: 4595-4602.
118. VOLLES, M.J. & P.T. LANSBURY, JR. 2003. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42: 7871-7878.
119. YOUDIM, M.B.H. 2003. What have we leamt from cDNA microarray gene expression studies about the role of iron in MPTP-induced neurodegeneration and Parkinson's disease. J. Neural Transm. Suppl. 65: 73-88.
120. YOUDIM, M.B.H. & P. RIEDERER. 1999. Iron in the brain, normal and pathological. In Elsevier's Encyclopedia of Neuroscience. Second edition, pp. 984-987. Elsevier. Amsterdam.
121. OESTREICHER, E., G.J. SENGSTOCK, P. RIEDERER et al. 1994. Degeneration of nigro-striatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660: 8-18.
122. SENGSTOCK, G.J., N.H. ZAWIA, C.W. OLANOW et al. 1997. Intranigral iron infusion in the rat: acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. Biol. Trace Elem. Res. 58: 177-195.
123. BEN-SHACHAR, D., G. ESHEL, J.P. FINBERG et al. 1991. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56: 1441-1444.
124. BEN-SHACHAR, D., N. KAHANA, L. KAMPEL et al. 2004. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46: 254-263.
125. BEN-SHACHAR, D. & M.B. YOUDIM. 1991. Intranigral iron injection induces behavioural and biochemical "parkinsonism" in rats. J. Neurochem. 57: 2133-2135.
126. MATSUOKA, Y., M. VILA, S. LINCOLN et al. 2001. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8: 535-539.
127. DONG, Z., B. FERGER, J. FELDON et al. 2002. Overexpression of Parkinson's disease associated alpha-synuclein A53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53: 1-10.
128. BJÖRKLUND, A. & D. KIRIK. 2003. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. TINS 26: 386-392,
129. GRIFFITHS, P.D. & A.R. CROSSMAN. 1993. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 4: 61-65.